Rapport Therapeutics, Inc. Common Stock cash flow to debt ratio of -761.69% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Rapport Therapeutics, Inc. Common Stock's free cash flow has decreased 31.02% from $-67.23M last year to $-88.09M, signaling decreasing performance

Rapport Therapeutics, Inc. Common Stock's debt to equity ratio is 0.02, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Rapport Therapeutics, Inc. Common Stock's debt has increased relative to shareholder equity from 0.00 last year to 0.02 today, signaling weakened financials

Rapport Therapeutics, Inc. Common Stock has negative EBITDA, making leverage ratio unreliable

Rapport Therapeutics, Inc. Common Stock earns at least as much interest as it pays. Interest obligations are fully covered.

Rapport Therapeutics, Inc. Common Stock has insufficient data to evaluate this check.

Rapport Therapeutics, Inc. Common Stock's short-term assets of $498.56M exceed its short-term liabilities of $19.05M

Rapport Therapeutics, Inc. Common Stock's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Rapport Therapeutics, Inc. Common Stock's return on equity of -24.79%, is lower than 15.00%, indicating bad performance

Rapport Therapeutics, Inc. Common Stock's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Rapport Therapeutics, Inc. Common Stock had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Rapport Therapeutics, Inc. Common Stock has negative free cash flow, indicating the company is burning cash rather than generating it

Rapport Therapeutics, Inc. Common Stock has negative free cash flow, indicating cash burn

Rapport Therapeutics, Inc. Common Stock's yearly earnings has decreased 42.37% since last year from $-78.31M to $-111.48M, signaling decreasing performance

Rapport Therapeutics, Inc. Common Stock's yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -25.34% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Rapport Therapeutics, Inc. Common Stock has insufficient revenue history to calculate 3-year revenue CAGR.

Rapport Therapeutics, Inc. Common Stock had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

Rapport Therapeutics, Inc. Common Stock had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Rapport Therapeutics, Inc. Common Stock has insufficient data to evaluate this check.

Rapport Therapeutics, Inc. Common Stock has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Rapport Therapeutics, Inc. Common Stock is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Rapport Therapeutics, Inc. Common Stock has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Rapport Therapeutics, Inc. Common Stock has insufficient data to evaluate this check.

Rapport Therapeutics, Inc. Common Stock has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Rapport Therapeutics, Inc. Common Stock has a price-to-book ratio of 4.15x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Rapport Therapeutics, Inc. Common Stock has a price-to-sales ratio of 97.92x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue